AstraZeneca: Tagrisso Met Primary Endpoint in Lung Cancer Trial
July 18 2016 - 2:46AM
Dow Jones News
By Razak Musah Baba
LONDON--AstraZeneca PLC's (AZN.LN) Tagrisso drug met its primary
endpoint in Phase III 2nd-line lung cancer trial, the
pharmaceutical company said Monday.
The research-based biopharmaceutical company said the Phase III
AURA3 trial met its primary endpoint, demonstrating superior
progression-free survival compared with standard platinum-based
doublet chemotherapy.
"These results confirm Tagrisso as a meaningful alternative to
benefit EGFR T790M lung cancer patients. The AURA3 results
demonstrate the benefits of our science-led approach that enabled
the rapid development of Tagrisso as a targeted treatment to
address the most common cause of resistance to a first-generation
EGFR-TKI for patients with metastatic EGFR-mutant lung cancer,"
said Sean Bohen, chief medical officer.
"We remain committed to exploring the potential of Tagrisso to
further extend its reach and help meet patient need," Mr. Bohen
said.
AstraZeneca is committed to exploring the full potential of
Tagrisso as monotherapy and in combination, for patients with lung
cancer.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
(END) Dow Jones Newswires
July 18, 2016 02:31 ET (06:31 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
